Esketamine - Impax Laboratories

Drug Profile

Esketamine - Impax Laboratories

Alternative Names: IPX 237; IPX237-C0001; IPX237-C0002; IPX237-L0001

Latest Information Update: 14 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IMPAX Laboratories
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 01 Jan 2015 Impax Laboratories completes a phase I trial in Healthy volunteers in Australia (ACTRN12614000444684)
  • 03 Jun 2014 Impax Laboratories completes a phase I trial in Undefined indication in Australia (ACTRN12613001097730)
  • 01 Oct 2013 Preclinical trials in Undefined indication in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top